KX 01

Drug Profile

KX 01

Alternative Names: KX-2391; KX01

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex; Hanmi Pharmaceutical; Kinex Pharmaceuticals; PharmaEssentia Corporation
  • Class Acetamides; Antineoplastics; Morpholines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Caspase stimulants; Interleukin 2 inhibitors; Keratinocyte inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Actinic keratosis
  • Phase II Psoriasis
  • Phase I/II Solid tumours
  • No development reported Acute myeloid leukaemia; Prostate cancer

Most Recent Events

  • 11 Dec 2017 Almirall and Athenex agree to co-promote and co-develop KX 01 in Europe, Russia and USA for actinic keratosis and other skin conditions
  • 28 Nov 2017 Adverse events and efficacy data from a phase I trial in Actinic keratosis released by Athenex
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(In the elderly) in USA (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top